NCT07436728 2026-03-27
A Study of TAK-505 in Adults With Solid Tumors
Takeda
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT06781125 2026-03-24
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
Phase 1/2 Not yet recruiting
NCT07028281 2026-03-03
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07268040 2026-01-12
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06737731 2026-01-09
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT07229612 2025-11-17
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05508620 2022-08-23
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT05441046 2022-07-06
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT02805166 2016-06-17
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT01391533 2016-04-13
SARMET
Sanofi
Phase 1 Completed
NCT00516438 2010-12-08
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
AstraZeneca
Phase 1 Completed